[{"id":"6553092f-70e4-434d-af85-c9de431dfb02","acronym":"","url":"https://clinicaltrials.gov/study/NCT03290937","created_at":"2021-01-18T16:15:28.855Z","updated_at":"2025-02-25T14:07:03.272Z","phase":"Phase 1","brief_title":"Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT03290937","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR • RAS mutation","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • irinotecan • utomilumab (PF-05082566) • Datalai (cetuximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 12/27/2017","start_date":" 12/27/2017","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-17"},{"id":"a823c207-e7e1-4f29-8a31-680d49989ddd","acronym":"AVIATOR","url":"https://clinicaltrials.gov/study/NCT03414658","created_at":"2021-01-18T16:50:49.598Z","updated_at":"2025-02-25T13:52:30.920Z","phase":"Phase 2","brief_title":"The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab \u0026 Utomilumab in Advanced HER2+ Breast Cancer","source_id_and_acronym":"NCT03414658 - AVIATOR","lead_sponsor":"Adrienne G. Waks","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • Bavencio (avelumab) • vinorelbine tartrate • utomilumab (PF-05082566)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/21/2018","start_date":" 06/21/2018","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-11-06"},{"id":"7d24d9e1-4dcb-42b7-a602-4f6bcfc0236d","acronym":"InCITe","url":"https://clinicaltrials.gov/study/NCT03971409","created_at":"2021-01-18T19:32:12.157Z","updated_at":"2024-07-02T16:35:04.267Z","phase":"Phase 2","brief_title":"Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer","source_id_and_acronym":"NCT03971409 - InCITe","lead_sponsor":"Hope Rugo, MD","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • Mektovi (binimetinib) • pegylated liposomal doxorubicin • Trodelvy (sacituzumab govitecan-hziy) • utomilumab (PF-05082566) • ivuxolimab (PF-04518600)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 07/08/2019","start_date":" 07/08/2019","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-13"},{"id":"e96ac04f-d494-4797-b71d-2048e4719923","acronym":"","url":"https://clinicaltrials.gov/study/NCT03318900","created_at":"2021-01-18T16:23:25.179Z","updated_at":"2024-07-02T16:35:05.191Z","phase":"Phase 1/2","brief_title":"T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer","source_id_and_acronym":"NCT03318900","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-A • PRAME • COL6A3","pipe":" | ","alterations":" PRAME expression","tags":["HLA-A • PRAME • COL6A3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PRAME expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Proleukin (aldesleukin) • utomilumab (PF-05082566) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 07/16/2018","start_date":" 07/16/2018","primary_txt":" Primary completion: 12/20/2023","primary_completion_date":" 12/20/2023","study_txt":" Completion: 12/20/2023","study_completion_date":" 12/20/2023","last_update_posted":"2024-05-08"},{"id":"00bbb33d-25be-4970-828c-31b893d1860f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03440567","created_at":"2021-01-18T16:58:12.301Z","updated_at":"2024-07-02T16:35:12.336Z","phase":"Phase 1","brief_title":"Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma","source_id_and_acronym":"NCT03440567","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD20 • CCND1","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imbruvica (ibrutinib) • Rituxan (rituximab) • Bavencio (avelumab) • cyclophosphamide • ifosfamide • etoposide IV • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • utomilumab (PF-05082566) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 04/02/2018","start_date":" 04/02/2018","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-03-29"},{"id":"66f13626-45a2-4288-b3f1-b38139944712","acronym":"NCI-2018-01118","url":"https://clinicaltrials.gov/study/NCT03217747","created_at":"2021-01-18T15:52:38.634Z","updated_at":"2024-07-02T16:35:12.950Z","phase":"Phase 1/2","brief_title":"Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies","source_id_and_acronym":"NCT03217747 - NCI-2018-01118","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • utomilumab (PF-05082566) • ivuxolimab (PF-04518600)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 173","initiation":"Initiation: 08/02/2017","start_date":" 08/02/2017","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-03-25"},{"id":"85bed745-9d5c-42bd-8992-b52ad10c6e36","acronym":"","url":"https://clinicaltrials.gov/study/NCT03364348","created_at":"2021-01-18T16:36:18.111Z","updated_at":"2024-07-02T16:36:02.232Z","phase":"Phase 1b","brief_title":"4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer","source_id_and_acronym":"NCT03364348","lead_sponsor":"George W. Sledge Jr.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Kadcyla (ado-trastuzumab emtansine) • Trazimera (trastuzumab-qyyp) • utomilumab (PF-05082566)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 10/30/2017","start_date":" 10/30/2017","primary_txt":" Primary completion: 02/15/2021","primary_completion_date":" 02/15/2021","study_txt":" Completion: 02/14/2022","study_completion_date":" 02/14/2022","last_update_posted":"2022-10-19"},{"id":"f8ab7eb9-fc51-41f7-b972-ba5fbb6a1f6c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01307267","created_at":"2021-01-18T05:19:14.063Z","updated_at":"2024-07-02T16:36:48.293Z","phase":"Phase 1","brief_title":"A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab","source_id_and_acronym":"NCT01307267","lead_sponsor":"Pfizer","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • utomilumab (PF-05082566)"],"overall_status":"Completed","enrollment":" Enrollment 190","initiation":"Initiation: 06/21/2011","start_date":" 06/21/2011","primary_txt":" Primary completion: 02/20/2019","primary_completion_date":" 02/20/2019","study_txt":" Completion: 02/20/2019","study_completion_date":" 02/20/2019","last_update_posted":"2020-03-17"}]